The economic benefits resulting from the first 8 years of the Global Programme to eliminate Lymphatic Filariasis (2000-2007)

PLoS Neglected Tropical Diseases

Volumn 4, Issue 6, 2010, Pages

  Chu, Brian K ^a   Hooper, Pamela J ^a   Bradley, Mark H ^b   McFarland, Deborah A ^c   Ottesen, Eric A ^a  

^a Lymphatic Filariasis Support Center   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; IVERMECTIN; ANTIFILARIAL AGENT;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE COURSE; DRUG COST; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LYMPHATIC FILARIASIS; MEDICAL INFORMATION; MORBIDITY; NEWBORN CARE; PARASITE TRANSMISSION; REMISSION; REVIEW; SENSITIVITY ANALYSIS; ARTICLE; ECONOMICS; HEALTH; METHODOLOGY;

COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS; PROGRAM EVALUATION; WORLD HEALTH;

EID: 77957007655     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000708     Document Type: Review

References (91)

1. Ottesen EA, Hooper PJ, Bradley M, Biswas G (2008) The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years. PLoS eNTDs. 317 p.
2. World Health Organization (2004) Annual Report on Lymphatic Filariasis 2003. Geneva. http://whqlibdoc.who.int/hq/2005/WHO_CDS_CPE_CEE_2005.2052.pdfp.
3. World Health Organization (2002) Annual Report on Lymphatic Filariasis 2001. Geneva. http://whqlibdoc.who.int/hq/2002/WHO_CDS_CPE_CEE_2002.2028.pdfp.
4. World Health Organization (2003) Annual Report on Lymphatic Filariasis 2002. Geneva. http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_CEE_2003.2038.pdfp.
5. World Health Organization (2005) Global Programme to Eliminate Lymphatic Filariasis: Progress report for 2004. Weekly Epidemiological Record 80: 202-212.
6. World Health Organization (2006) Global Programme to Eliminate Lymphatic Filariasis: Progress report on mass drug administrations in 2005. Weekly Epidemiological Record 22: 221-232.
7. World Health Organization (2007) Global Programme to Eliminate Lymphatic Filariasis: Progress report on mass drug administration in 2006. Weekly Epidemiological Record 82: 361-380.
8. World Health Organization (2008) Global Programme to Eliminate Lymphatic Filariasis: Progress report on mass drug administration in 2007. Weekly Epidemiological Record 83: 333-348.
9. Health Action International (2008) Medicine Prices, Availability, Affordability, and Price Components, http://www.haiweb.org/.
10. Management Science for Health (2008) International Drug price Indicator Guide, http://erc.msh.org.
11. International Labour Organization LABORSTA, http://laborsta.ilo.org/.
12. World Bank World Development Indicators Online, http://publications.worldbank.org/WDI/.
13. International Labour Organization Minimum Wages Database, http://www.ilo.org/travaildatabase/servlet/minimumwages.
14. U.S. Department of State (2008) Human Rights, Country Reports, http://www.state.gov/g/drl/rls/hrrpt/.
15. International Monetary Fund (2008) World Economic Outlook Database, April 2008, http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/index.aspx.
16. Ottesen EA (2006) Lymphatic filariasis: Treatment, control and elimination. Advances in Parasitology 61: 395-441.
17. World Health Organization (2006) Life Tables for WHO Member States, http://apps.who.int/whosis/database/life_tables/life_tables.cfm.
18. Stolk W, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD (2003) Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: A simulation study. Journal of Infectious Diseases 188: 1371-1381.
19. Stolk WA, de Vlas SJ, Habbema JD (2006) Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J 5: 5.
20. Shenoy RK, Suma TK, Kumaraswami V, Rahmah N, Dhananjayan G, et al. (2009) Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection. Annals of Tropical Medicine & Parasitology 103: 235-247.
21. Partono F, Maizels RM, Purnomo (1989) Towards a filariasis-free community: evaluation of filariasis control over an eleven year period in Flores, Indonesia. Trans R Soc Trop Med Hyg 83: 821-826.
22. Casley-Smith JR, Jamal S, Casley-Smith JR (1993) Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin) and the effects of diethylcarbamazine (DEC). Annals of Tropical Medicine & Parasitology 87: 247-258.
23. Tisch DJ, Alexander ND, Kastens WA, Siba PM, Bockarie MJ, et al. (2009) Acute morbidity events during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea. Unpublished manuscript.
24. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, et al. (2002) Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347: 1841-1848.
25. Partono F, Purnomo, Oemijati S, Soewarta A (1981) The long term effects of repeated diethylcarbamazine administration with special reference to microfilaraemia and elephantiasis. Acta Trop 38: 217-225.
26. Partono F (1985) Treatment of elephantiasis in a community with timorian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 79: 44-46.
27. Meyrowitsch DW, Simonsen PE, Makunde WH (1996) Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: Comparative efficacy of a low monthly dose and medicated salt. Transactions of the Royal Society of Tropical Medicine and Hygiene 90: 74-79.
28. Ciferri F, Siliga N, Long G, Kessel JF (1969) A filariasis-control program in American Samoa. American Journal of Tropical Medicine and Hygiene 18: 369-378.
29. Fan PC, Peng HW, Chen CC (1995) Follow-up investigations on clinical manifestations after filariasis eradication by diethylcarbamazine medicated common salt on Kinmen (Quemoy) Islands, Republic of China. Journal of Tropical Medicine and Hygiene 98: 461-464.
30. Das L, Subramanyam Reddy G, Pani S (2003) Some observations on the effect of Daflon (micronized purified flavonoid fraction of Rutaceae aurantiae) in bancroftian filarial lymphoedema. Filaria Journal 2.
31. Mackenzie C, Lazarus W, Mwakitalu M, Mwingira U, Malecela M (2009) Lymphatic Filariasis: Patients and the Global Elimination Programme. Annals of Tropical Medicine and Parasitology 103, Supplement No. 1: S1-S11.
32. Addiss DG, Brady MA (2007) Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 6.
33. Krishnamoorthy K (1999) Estimated costs of acute adenolymphangitis to patients with chronic manifestations of bancroftian filariasis in India. Indian Journal of Public Health 43: 58-63.
34. Nanda B, Krishnamoorthy K (2003) Treatment seeking behaviour and costs due to acute and chronic forms of lymphatic filariasis in urban areas in south India. Tropical Medicine & International Health 8: 56-59.
35. Ramaiah KD, Ramu K, Vijay Kumar KN, Guyatt H (1996) Epidemiology of acute filarial episodes caused by Wucheria bancrofti infection in two rural villages in Tamil Nadu, south India. Transactions of the Royal Society of Tropical Medicine and Hygiene 90: 639-643.
36. Ramaiah KD, Guyatt H, Ramu K, Vanamail P, Pani SP, et al. (1999) Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Tropical Medicine & International Health 4: 19-25.
37. Babu BV, Nayak AN, Dhal K, Acharya AS, Jangid PK, et al. (2002) The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Tropica 82: 31-38.
38. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S (1996) The economic burden of lymphatic filariasis in northern Ghana. Annals of Tropical Medicine & Parasitology 90: 39-48.
39. Pani S, Yuvaraj J, Vanamail P, Dhanda V, Michael E, et al. (1995) Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine & Hygiene 89: 72-74.
40. Ramaiah KD, Radhamani MP, John KR, Evans DB, Guyatt H, et al. (2000) The impact of lymphatic filariasis on labour inputs in south India: Results of a multi-site study. Annals of Tropical Medicine and Parasitology 94: 353-364.
41. Babu BV, Nayak AN, Dhal K (2005) Epidemiology of episodic adenolymphangitis: a longitudinal prospective surveillance among a rural community endemic for bancroftian filariasis in coastal Orissa, India. BMC Public Health 5: 50.
42. Gyapong JO, Gyapong M, Adjei S (1996) The epidemiology of acute adenolymphangitis due to lymphatic filariasis in northern Ghana. American Journal of Tropical Medicine & Hygiene 54: 591-595.
43. Kessel JF (1957) Disabling effects and control of filariasis. American Journal of Tropical Medicine and Hygiene 6: 402-414.
44. Gasarasi DB, Premji ZG, Mujinja PGM, Mpembeni R (2000) Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania. Acta Tropica 75: 19-28.
45. Sabesan S, Krishnamoorthy K, Pani SP, Panicker KN (1992) Mandays lost due to repeated attacks of lymphatic filariasis. Trends in Life Sciences 7: 5-7.
46. Ramaiah KD, Das PK, Michael E, Guyatt H (2000) The economic burden of lymphatic filariasis in India. Parasitology Today 16: 251-253.
47. Burton AW (1961) The Valuation of Human Capital. Journal of Political Economy 69: 425-436.
48. Onwujekwe O, Chima R, Okonkwo P (2000) Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holo-endemic Nigerian communities. Health Policy 54: 143-159.
49. Frick KD, Basilion EV, Hanson CL, Colchero MA (2003) Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol 10: 121-132.
50. McFarland D, Menzies N, Njoumemi Z, Onwujekwe O (August 2005) Study of cost per treatment with ivermectin using the CDTI strategy. African Programme for Onchocerciasis Control (APOC).
51. Ramaiah KD, Ramu K, Guyatt H, Kumar KNV, Pani SP (1998) Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Tropical Medicine & International Health February 3: 108-115.
52. WHO-CHOICE (2008) WHO, Tables of Costs and Prices used in WHOCHOICE Analysis, http://www.who.int/choice/costs/en/.
53. World Health Organization (2003) Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis; Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al. (2003) Geneva: World Health Organization.
54. Goldman AS, Guisinger VH, Aikins M, Amarillo MLE, Belizario VY, et al. (2007) National Mass Drug Administration Costs for Lymphatic Filariasis Elimination. PLoS Negl Trop Dis 1: e67.
55. March HN, Laigret J, Kessel JF, Bambridge B (1960) Reduction in the prevalence of clinical filariasis in Tahiti following adoption of a control program. Am J Trop Med Hyg 9: 180-184.
56. Ramu K, Ramaiah KD, Guyatt H, Evans D (1996) Impact of lymphatic filariasis on the productivity of male weavers in a south Indian village. Transactions of the Royal Society of Tropical Medicine & Hygiene 90: 669-670.
57. Rao CK, Sharma SP (1986) Control of filariasis in India. J Commun Dis 18: 276-282.
58. Pani SP, Krishnamoorthy K, Prathibha J, Rao AS (1989) Diethylcarbamazine and supportive measures for the treatment of brugian filariasis. Natl Med J India 89: 260-263.
59. Evans DB, Gelband H, Vlassoff C (1993) Social and economic factors and the control of lymphatic filariasis: A review. Acta Tropica 53: 1-26.
60. Haddix AC (1999) An economic evaluation of integrating lymphatic filariasis elimination into APOC. The Hague.
61. World Health Organization (1997) Resolution of the Executive Board of the WHO: Elimination of Lymphatic Filariasis as a Public Health Problem. Geneva: 50th World Health Assembly.
62. Rao CK, Chandrasekharan A, Cherian C (1982) Frequency and duration of acute filarial attacks in persons in Brugia malayi endemic community. Indian J Med Res 75: 813-815.
63. Ravindranathan TC, Sethumadhavan KVP, Roychowdhury SP, Babu CS, Kanoujia KH, et al. (1980) Seasonal variation in microfilaraemia (bancrofti) density and filaria disease. Journal of Communicable Disease. pp 73-77.
64. Muhondwa EPY (1983) Community participation in filariasis control: the Tanzania experiment. Geneva: World Health Organization Special Programme for Research and Training in Tropical Diseases.
65. Ntuli Malecela M, Lazarus W, Mwingira U (2009) Eliminating LF: A Progress Report from Tanzania. Journal of Lymphoedema 4: 2-4.
66. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14: 171-189.
67. Attanayake N, Fox-Rushby J, Mills A (2000) Household costs of 'malaria' morbidity: a study in Matale district, Sri Lanka. Tropical Medicine & International Health 5: 595-606.
68. Wegesa P, McMahon JE, Abaru DE, Hamilton PJS, Marshall TF, et al. (1979) Tanzania filariasis project: Survey methodology and clinical manifestations of bancroftian filariasis. Acta Tropica 36: 369-377.
69. Mwobobia IK, Muniu EM, Kombe Y (2000) Hydrocelectomy: A proxy for hydrocele prevalence in coastal Kenya. Annals of Tropical Medicine and Parasitology 94: 479-484.
70. Kanjilal S, Rheingans RD, Haddix AC, Addiss DG (2004) Cost analysis of a lymphedema treatment program, Leogane, Haiti. Filarial Journal.
71. Krishnamoorthy K, Ramu K, Srividya A, Appavoo NC, Saxena NB, et al. (2000) Cost of mass annual single dose diethylcarbamazine distribution for the large scale control of lymphatic filariasis. Indian Journal of Medical Research 111: 81-89.
72. World Health Organization Press Office. MAJOR PRIVATE SECTOR PARTNER, MERCK, WELCOMED TO LYMPHATIC FILARIASIS CONTROL EFFORT. World Health Organization. 23 October 1998. Press Release WHO/76. http://www.who.int/inf-pr-1998/en/pr98-76.html.
73. World Health Organization Press Office. WHO, SMITHKLINE BEECHAM TO COOPERATE ON ELEPHATIASIS ELIMINATION. World Health Organization. 26 January 1998. Press Release WHO/12. http://www.who.int/inf-pr-1998/en/pr98-12.html.
74. Benton B (1998) Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: An overview. Annals of Tropical Medicine and Parasitology 92: S33-S39.
75. Frick KD, Hanson CL, Jacobson GA (2003) Global burden of trachoma and economics of the disease. Am J Trop Med Hyg 69: 1-10.
76. Mills A, Lubell Y, Hanson K (2008) Malaria eradication: the economic, financial and institutional challenge. Malar J 7 Suppl 1: S11.
77. Sachs J, Malaney P (2002) The economic and social burden of malaria. Nature 415: 680-685.
78. Gallup JL, Sachs JD (2001) The economic burden of malaria. Am J Trop Med Hyg 64: 85-96.
79. Brady MA, Hooper PJ, Ottesen EA (2006) Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends in Parasitology 22: 285-291.
80. Molyneux D (2003) Lymphatic Filariasis (Elephantiasis) Elimination: A public health success and development opportunity. Filaria J 2: 13.
81. Haddix AC, Kestler A (2000) Lymphatic filariasis: economic aspects of the disease and programmes for its elimination. Transactions of the Royal Society of Tropical Medicine & Hygiene 94: 592-593.
82. Perera M, Whitehead M, Molyneux D, Weerasooriya M, Gunatilleke G (2007) Neglected Patients with a Neglected Disease? A Qualitative Study of Lymphatic Filariasis. PLoS Negl Trop Dis 1: e128.
83. Coreil J, Mayard G, Louis-Charles J, Addiss D (1998) Filarial elephantiasis among Haitian women: social context and behavioural factors in treatment. Tropical Medicine & International Health June 3: 467-473.
84. Hunter JM (1992) Elephantiasis: A disease of development in north east Ghana. Social Science and Medicine 35: 627-649.
85. Gyapong M, Gyapong J, Weiss M, Tanner M (2000) The burden of hydrocele on men in Northern Ghana. Acta Trop 77: 287-294.
86. Ramaiah KD, Kumar KNV (2000) Effect of lymphatic filariasis on school children. Acta Tropica 76: 197-199.
87. Dreyer G, Ottesen EA, Galdino E, Andrade L, Rocha A, et al. (1992) Renal abnormalities in microfilaremic patients with Bancroftian filariasis. American Journal of Tropical Medicine and Hygiene 46: 745-751.
88. Chhotray GP, Ranjit MR, Mohapatra M (2000) Occurrence of asymptomatic microscopic haematuria in a filarial endemic area of Orissa, India. J Commun Dis 32: 85-93.
89. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, et al. (2005) Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bulletin of the World Health Organization 83: 34-42.
90. Hengge UR, Currie BJ, Jager G, Lupi O, Schwartz RA (2006) Scabies: a ubiquitous neglected skin disease. The Lancet 6: 769-779.
91. Bockarie MJ, Molyneux DH (2009) The end of lymphatic filariasis? BMJ 338: b1686.